Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression Authors
Mood Disorders (SM Strakowski, Section Editor)
First Online: 24 July 2013 DOI:
Cite this article as: Dell’Osso, B., Ketter, T.A., Cremaschi, L. et al. Curr Psychiatry Rep (2013) 15: 378. doi:10.1007/s11920-013-0378-z Part of the following topical collections: Topical Collection on Mood Disorders Abstract
Bipolar depression is considered the most difficult-to-treat phase of bipolar disorder, in relation to its pervasiveness and efficacy and/or tolerability limitations of available treatments. Indeed, most mood stabilizers and atypical antipsychotics are not as effective in ameliorating depressive compared with manic symptoms, and entail substantial tolerability limitations. However, the use of antidepressants is highly controversial, as their efficacy appears less robust in bipolar compared with unipolar depression. In addition, antidepressants, in spite of generally having adequate somatic tolerability, in BD may be associated with a higher risk of manic/hypomanic switch, suicidality and rapid cycling. Among alternative pharmacological strategies, compounds with stimulant and pro-dopaminergic effects, such as methylphenidate, modafinil, armodafinil and pramipexole, have showed potential antidepressant activity, even though their use in clinical practice has been limited by the paucity of controlled evidence. This article seeks to review available evidence about the use of the aforementioned compounds in the treatment of bipolar depression. Findings from reviewed studies suggested that pro-dopaminergic compounds, such as pramipexole and stimulants/stimulant-like agents, deserve consideration as adjunctive therapies in bipolar depressed patients, at least in some subgroups of patients. Nevertheless, caution regarding their use is recommended as further clinical trials with larger samples and longer follow-up periods are necessary to clarify the roles of these medications in bipolar depression.
Keywords Bipolar depression Stimulants Dopamine agonists Pramipexole Methylphenidate Modafinil Armodafinil Mood disorders Psychiatry
This article is part of the Topical Collection on
Mood Disorders References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ghaznavi S, Deckersbach T. Rumination in bipolar disorder: evidence for an unquiet mind. Biol Mood Anxiety Disord. 2012;2:2.
Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat. 2012;2012:684725.
Ghaemi SN, Soldani F, Hsu DJ. Evidence-based pharmacotherapy of bipolar disorder. Int J Neuropsychopharmacol. 2003;6:303–8.
Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr. 2008;13:790–5.
•• Yatham LN, Kennedy SH, Schaffer A, et al. CANMAT and ISBD collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2009;11:225–55.
This second update of CANMAT guidelines, in conjunction with the International Society for Bipolar Disorders (ISBD), reviews new evidence, which provides an expanded look at bipolar II disorder
•• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81–109.
The purpose of these guidelines is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults
• Dell’Osso B, Ketter TA. Use of adjunctive stimulants in adult bipolar depression. Int J Neuropsychopharmacol. 2013;16:55–68.
This review provides an updated perspective on the use of stimulants and stimulant-like medications in adult bipolar depression, considering not only recent randomized controlled trials, but also open naturalistic studies, in order to clarify the strengths and limitations of using these agents
Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003;110:1119–27.
Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11:58–65.
•• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–6.
This is the first placebo-controlled trial conducted in order to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression. Pramipexole was found to be a safe and effective antidepressant among patients with bipolar depression
•• Zarate Jr CA, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60.
This study was undertaken as proof of the concept that dopamine agonists will be effective in patients with bipolar II depression. Pramipexole was found to have significant antidepressant effects in patients with bipolar II depression
Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10:399–406.
Möller JC, Oertel WH, Köster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20:602–10.
Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–7.
Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;16(2):CD006722.
Chavez B, Sopko Jr MA, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2009;43:1084–95.
Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75:711–21.
Katon W, Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. Am J Psychiatry. 1980;137:963–5.
Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics. 1987;28:455–61.
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33:1477–502.
Schmitt KC, Reith ME. The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One. 2011;6:e25790.
Vosburg SK, Hart CL, Haney M, et al. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend. 2010;106:233–6.
Niemegeers P, Maudens KE, Morrens M, et al. Pharmacokinetic evaluation of armodafinil for the treatment of depression. Expert Opin Drug Metab Toxicol. 2012;8:1189–97.
Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353:476–86.
EMEA. Questions and answers on the review of medicines containing Modafinil. European Medicines Agency. EMA/725532/2010; 2010.
•• Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23:346–88.
These guidelines, recently updated and based explicitly on the available evidence, specify the scope and target of treatment for bipolar disorder
Pfennig A, Bschor T, Baghai T, et al. S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations. Nervenarzt. 2012;83:568–86.
Goldberg JF, Frye MA, Dunn RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156:798.
Gupta S, Vincent JL, Frank B. Pramipexole: augmentation in the treatment of depressive symptoms. CNS Spectr. 2006;11:172–5.
Akdeniz F, Aldemir E, Vahip S. The role of low-dose pramipexole in the treatment of treatment-resistant bipolar depression: a case report. Turk Psikiyatri Derg. 2009;20:94–8.
Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother. 2003;37:1807–9.
Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000;12:137–40.
Guy W. Clinical global impression. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health; 1976.
Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34:137–41.
• Lattanzi L, Dell’Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002;4:307–14.
Data from this naturalistic study suggest that pramipexole adjunction to antidepressant treatment may be effective and well tolerated in patients with resistant major depression.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429.
• Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety. 2004;20:131–8.
This study, conducted in order to evaluate long-term safety and tolerability of pramipexole, shows that pramipexole augmentation of antidepressant treatment was relatively safe and presumably effective in the long-term course of treatment resistant depression.
• El-Mallakh RS, Penagaluri P, Kantamneni A, et al. Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr Q. 2010;81:207–13.
This naturalistic review was conducted in order to determine the long-term outcome of adjunctive pramipexole, which, in the end, appears to be adequate, with apparent maintenance of effect for over 9 months.
•• Burdick KE, Braga RJ, Nnadi CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012;73:103–12.
Patients with bipolar disorder suffer from significant cognitive impairment. This recent study revealed a potentially beneficial effect of pramipexole on cognition in a subgroup of bipolar patients
• Dell’Osso B, Timtim S, Hooshmand F, Miller S, Wang PW, Hill SJ, Portillo N, Ketter TA. Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. J Affect Disord. 2012. doi:
Preliminary observation from this recent study suggests that modafinil, compared to pramipexole, may be better tolerated for longer-term BD treatment.
El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Disord. 2000;2:56–9.
Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6:416–20.
Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol. 2006;26:516–8.
Parker G, Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr Scand. 2010;121:308–14.
Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378–81.
Nasr S. Modafinil as adjunctive therapy in depressed outpatients. Ann Clin Psychiatry. 2004;16:133–8.
Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord. 2006;95:111–4.
•• Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1242–9.
This study, conducted to evaluate the efficacy and safety of adjunctive modafinil in bipolar depression, suggests that adjunctive modafinil at doses of 100
200 mg a day may improve depressive symptoms in patients with bipolar disorder
•• Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry. 2010;71:1363–70.
In this proof-of-concept study, adjunctive armodafinil 150 mg/d seemed to improve depressive symptoms and was generally well tolerated in patients with bipolar depression
Aiken CB. Pramipexole in psychiatry: a systematic review of the literature. J Clin Psychiatry. 2007;68:1230–6.
Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59:60–4.
Erfurth A, Michael N, Stadtland C, et al. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology. 2002;45:33–6.
Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12:S7–14.
Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5:378–88.
Bennett Jr JP, Piercey MF. Pramipexole: a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci. 1999;163:25–31.
Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 1998;71:295–301.
Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm. 1997;104:209–28.
Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat Disord. 2001;7:213–23.
Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist Pramipexole. Curr Med Res Opin. 2009;25:2977–87.
Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71:43–64.
Belmaker RH. Modafinil add-on in the treatment of bipolar depression. Am J Psychiatry. 2007;164:1143–5.
Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia. 2002;40:2257–67.
Fountoulakis KN, Siamouli M, Panagiotidis P, et al. Ultra short manic-like episodes after antidepressant augmentation with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:891–2.
Maremmani I, Pacini M, Lamanna F, et al. Mood stabilizers in the treatment of substance use disorders. CNS Spectr. 2010;15:95–109.
Plante DT. Treatment-emergent hypomania or mania with modafinil. Am J Psychiatry. 2008;165:134–5.
DelBello MP, Soutullo CA, Hendricks W, et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord. 2001;3:53–7.
Soutullo CA, DelBello MP, Ochsner JE, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord. 2002;70:323–7.
Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry. 2006;67:554–66.
Ketter TA, Wang PW. Antidepressants, anxiolytic/hypnotics and other medications: pharmacokinetics, drug inetractions, adverse effects and administration. In: Ketter T, editor. Handbook of diagnosis and treatment of bipolar disorder. Washington: American Psychiatric Publishing; 2010. p. 611–60.
Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychopharmacol. 1999;14:1–18.
Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics. 1991;32:203–8.
Rosenberg PB, Ahmed I, Hurwitz S. Methylphenidate in depressed medically ill patients. J Clin Psychiatry. 1991;52:263–7.
Rozans M, Dreisbach A, Lertora JJ, et al. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol. 2002;20:335–9.
Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry. 1995;152:929–31.
Manove E, Levy B. Cognitive impairment in bipolar disorder: an overview. Postgrad Med. 2010;122:7–16.
Sawaguchi T. The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci Res. 2001;41:115–28.
Morein-Zamir S, Turner DC, Sahakian BJ. A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull. 2007;33:1298–306.
Repantis D, Schlattmann P, Laisney O, et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187–206.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2013